Fresenius SE & Co KGaA
XETRA:FRE

Watchlist Manager
Fresenius SE & Co KGaA Logo
Fresenius SE & Co KGaA
XETRA:FRE
Watchlist
Price: 33.31 EUR 1.59% Market Closed
Market Cap: 18.8B EUR
Have any thoughts about
Fresenius SE & Co KGaA?
Write Note

Net Margin
Fresenius SE & Co KGaA

-1.8%
Current
2%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1.8%
=
Net Income
-383m
/
Revenue
21.9B

Net Margin Across Competitors

Country DE
Market Cap 18.8B EUR
Net Margin
-2%
Country US
Market Cap 91.8B USD
Net Margin
1%
Country US
Market Cap 87.7B EUR
Net Margin
1%
Country US
Market Cap 73B USD
Net Margin
1%
Country DE
Market Cap 24.9B EUR
Net Margin
3%
Country US
Market Cap 20.1B USD
Net Margin
3%
Country US
Market Cap 18.3B USD
Net Margin
9%
Country US
Market Cap 13.7B USD
Net Margin
7%
Country DE
Market Cap 12.4B EUR
Net Margin
3%
Country AU
Market Cap 13.4B AUD
Net Margin
6%
Country US
Market Cap 8.6B USD
Net Margin
13%
No Stocks Found

Fresenius SE & Co KGaA
Glance View

Market Cap
18.8B EUR
Industry
Health Care

Fresenius SE & Co KGaA is a global healthcare group rooted in Germany, dedicated to providing high-quality medical services and products to patients worldwide. Founded in 1912, the company has grown into a diverse organization with a strong focus on life-saving therapies in renal care, hospital services, and pharmaceutical manufacturing. With its subgroups—Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed—the company operates across different segments that collectively support its vision of enhancing patient outcomes, improving quality of care, and meeting the increasing demand for healthcare services in an aging global population. By leveraging an extensive network of healthcare facilities, innovative product pipelines, and a commitment to sustainability, Fresenius positions itself as a leader in the dynamic healthcare landscape. For investors, Fresenius SE & Co KGaA represents an opportunity to engage with a stable yet growth-oriented enterprise. The company has consistently demonstrated resilience, even amidst market fluctuations, reflecting a strong financial foundation and strategic leadership. With the global healthcare market projected to expand, driven by an increase in chronic diseases and the need for advanced medical solutions, Fresenius is well-poised to capture significant market share. Its focus on innovation, particularly in personalized medicine and digital health, underscores a forward-thinking approach that aligns with evolving patient needs. As a long-term investment option, Fresenius' commitment to enhancing healthcare accessibility and efficiency not only offers the potential for financial returns but also contributes positively to global health outcomes, making it a compelling choice for investors looking for a balance of impact and profit.

FRE Intrinsic Value
70.19 EUR
Undervaluation 53%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1.8%
=
Net Income
-383m
/
Revenue
21.9B
What is the Net Margin of Fresenius SE & Co KGaA?

Based on Fresenius SE & Co KGaA's most recent financial statements, the company has Net Margin of -1.8%.